The latest international news, analysis and features on the HIV epidemic from Avert. Share your views and expertise with your peers in the comments box below the articles.
Long-acting, injectable cabotegravir is as effective as daily PrEP pills at preventing HIV among cisgender men and transgender women who have sex with men.
If you’re living with HIV and wondering how the new coronavirus may affect you, here are some tips to help you look after yourself.
Modelling finds PrEP has the potential to avert between 3 and 8% of HIV infections in 13 African and Caribbean countries by 2030 if three key populations can access it
Viral load testing trial finds 49% are virally unsuppressed while one in five are failing their treatment with suspected drug resistance.
Research on PrEP safety for pregnant women and their babies finds no adverse effects – but knowledge gaps remain.
Study with transgender women suggests taking on-demand PrEP with hormone therapy may result in drug levels too low for HIV prevention.
The largest-ever study examining the effectiveness of condoms for anal sex finds remarkably low levels of failure, and calls to label their use in this way.
New World Health Organization policy indicates that countries should replace western blotting and line immunoassays, which can only be conducted in laboratories, with simpler methods such as rapid diagnostic tests.
Findings from France and Canada suggest it is safe to offer men who have sex with men a choice between daily and ‘on-demand’ PrEP if they are not having frequent sex.